This study evaluated outcomes in patients undergoing resection for lung cancer who were found at surgery to have pleural carcinomatosis. 2.9% of registry patients were identified, of whom 49% had a macroscopic complete resection. 5-year survival in those without other metastatic disease was 29%. 5-year survival in those undergoing macroscopic comp
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Lung
June 24, 2015
The ELCAP data set was evaluated for pts identified with non-solid nodules at baseline or during follow-up. 2392 (4.2%) pts had nonsolid nodules at baseline, of which 73 were diagnosed as adenocarcinoma. A new nodule was identified in an additional 485 (0.7%) pts, of whom 11 were diagnosed with adenocarcinoma. Nonsolid nodules improved in 66% of
June 23, 2015
This video demonstrates the performance of a VATS trisegmentectomy on a patient with a left upper lobe cT1aN0 adenocarcinoma.
June 14, 2015
Trials evaluating the use of surgery in stage IIIB NSCLC are lacking. This study goes some way to address that and demonstrates that surgery as part of multi-modality therapy may result in a survival benefit.
June 12, 2015
This meta-analysis of published studies evaluated outcomes of multimodality therapy including resection for superior sulcus NSCLC invading the spine. 134 articles were evaluated, which included 135 patients. 63% had induction therapy, and all underwent en bloc resection. 52% had adjuvant therapy. Survival at 3,5, and 10 years was 57%, 42%, and 27
May 28, 2015
In presentations given at the 2014 STSA Annual Meeting in Tucson, Arizona, two experts address lung cancer screening.
May 22, 2015
In this retrospective review of 336 patients treated surgically for early stage NSCLC, the prognostic value of PET SUV was evaluated. Risks of recurrence and death increased steadily as SUV increased.
May 22, 2015
This interesting article summarizes the potential benefits of exercise in patients with lung cancer, including improved exercise capacity and quality of life, and reduced postoperative complications and length of postoperative stay. This modality is safe, and is likely underutilized in this patient population.
May 20, 2015
A pooled analysis of outcomes from two randomized trials involving SBRT or surgery for operable patients with clinical early stage NSCLC was performed. The number of patients was small (58 total) and the follow-up was a median of 35-40 mos. Overall 3-year survival was better in the SBRT group (95% vs 79%; p=0.037) whereas recurrence free survival di
May 19, 2015
Pts with suspected lung cancer underwent sampling of normal-appearingbronchial epithelial cells in the main bronchi, unrelated to the suspected tumor. Gene expression was analyzed and classified. Classification for cancer was about 75% accurate.